6,7-dimethoxy-4-piperazino-9H-pyrimido<4,5-b>indole | 106635-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6,7-dimethoxy-4-piperazino-9H-pyrimido<4,5-b>indole
• 英文别名: 6,7-dimethoxy-4-(piperazin-1-yl)-9H-pyrimido[4,5-b]indole；6,7-dimethoxy-4-piperazino-9H-pyrimido[4,5-b]indole；6,7-dimethoxy-4-piperazin-1-yl-9H-pyrimido[4,5-b]indol；6,7-dimethoxy-4-piperazin-1-yl-9H-pyrimido[4,5-b]indole
• CAS: 106635-00-1
• 化学式: C₁₆H₁₉N₅O₂
• 分子量: 313.359
• InChiKey: QEYULVQHTAIOTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6,7-dimethoxy-4-piperazino-9H-pyrimido<4,5-b>indole 在 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 7.0h， 生成 6,7-dimethoxy-4--9H-pyrimido<4,5-b>indole
  参考文献：
  名称：

  6,7-二甲氧基嘧啶[4,5- b ]-吲哚的合成作为潜在的降压药†

  摘要：

  使用5,7-二甲氧基-2-氨基-3-吲哚羧酸乙酯作为合成子，描述了在2位和4位带有烷基氨基部分的标题化合物的合成路线。一些化合物显示出降压活性。

  DOI：

  10.1002/jhet.5570250607
• 作为产物：
  描述：

  1-氯-4,5-二甲氧基-2-硝基苯 在 1,4-二氧六环 、 吡啶 、 potassium tert-butylate 、 sodium methylate 、 溶剂黄146 、 锌 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 60.25h， 生成 6,7-dimethoxy-4-piperazino-9H-pyrimido<4,5-b>indole
  参考文献：
  名称：

  WO2006/116733

  摘要：

  公开号：

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Hurley Laurence H.

  公开号：US20130302303A1

  公开（公告）日：2013-11-14

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R 1 , R 2 , R 3 , X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了具有在蛋白激酶介导的疾病和病症（如癌症）治疗中的用途的蛋白激酶抑制剂。本发明的化合物具有以下结构：包括立体异构体，前药和其药学上可接受的盐，其中A是从以下环基团中选择的环基团：其中R1、R2、R3、X、Z、L1、Cycl1、L2和Cycl2如本文所定义。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。
• Protein kinase inhibitors
  申请人：Hurley H. Laurence

  公开号：US20050239793A1

  公开（公告）日：2005-10-27

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了具有治疗蛋白激酶介导疾病和病况（如癌症）的效用的蛋白激酶抑制剂。本发明的化合物具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中A是从以下环基中选择的环基：并且R1、R2、R3、X、Z、L1、Cycl1、L2和Cycl2的定义如本文所述。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。
• Protein Kinase Inhibitors
  申请人：Hurley H. Laurence

  公开号：US20080051414A1

  公开（公告）日：2008-02-28

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R 1 , R 2 , R 3 , X, Z, L 1 , Cycl 1 , L 2 and Cycl 2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了具有在治疗蛋白激酶介导的疾病和病状（如癌症）中的用途的蛋白激酶抑制剂。本发明的化合物具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中A是从以下环基中选择的环基：并且其中R1、R2、R3、X、Z、L1、Cycl1、L2和Cycl2的定义如本文所述。本发明还揭示了包含本发明化合物的组合物，以及与其使用相关的方法。
• Substituted tricyclic compounds as protein kinase inhibitors
  申请人：Arizona Board of Regents on Behalf of The University of Arizona

  公开号：US07312226B2

  公开（公告）日：2007-12-25

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了具有在蛋白激酶介导的疾病和情况（如癌症）治疗效用的蛋白激酶抑制剂。本发明的化合物具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中A是从以下环基中选择的环基：而R1、R2、R3、X、Z、L1、Cycl1、L2和Cycl2的定义如本文所述。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。
• Substituted tricyclic compound as protein kinase inhibitors
  申请人：Arizona board of Regents on Behalf of the University of Arizona

  公开号：US07326713B2

  公开（公告）日：2008-02-05

  Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  本发明揭示了在蛋白激酶介导的疾病和情况（如癌症）的治疗中具有效用的蛋白激酶抑制剂。本发明的化合物具有以下结构：包括立体异构体、前药和其药物可接受的盐，其中A是从以下环基中选择的环基：其中R1、R2、R3、X、Z、L1、Cycl1、L2和Cycl2的定义如本文所述。本发明还揭示了含有本发明化合物的组合物，以及与其使用相关的方法。